Validation of a Traditional Medicine, Achyrocline satureioides Infusion, for the Improvement of Mild Respiratory Infection Symptoms: A Randomized, Placebo-Controlled and Open-Label Clinical Trial.

ingentiumby ingentium

In Clinical Trials Literature.

Publication date: Jun 09, 2025

Background/Objectives: The need for the scientific validation of traditional and folk medicine knowledge has emerged lately. Achyrocline satureioides inflorescences have been widely used for the management of mild viral respiratory infection symptoms in South Brazil, Uruguay and Argentina. We intended to assess the therapeutic efficacy of a 14-day course with A. satureioides for mild viral respiratory infection symptoms. Methods: We conducted a randomized, open-label, placebo-controlled trial. Before COVID-19 (SARS-CoV-2) diagnostic tests, participants were randomly assigned to one of two experimental groups: A. satureioides or Malus domestica infusions, with instructions to use the infusions twice a day for 14 days. Our primary endpoint was the recovery time for respiratory symptoms in the overall analysis; the secondary outcomes were the recovery time for non-respiratory symptoms and for stratified analysis, taking into account the vaccination status against SARS-CoV-2 and COVID-19 infection; and the rate of symptom recovery was also evaluated. Results: The A. satureioides infusion significantly accelerated the resolution of sore throat and sneezing compared with the control group. The participants with COVID-19 who had not been vaccinated and received A. satureioides infusion recovered faster from sore throat, body ache, fever and cough, and showed a shorter median survival time for symptom resolution. The SARS-CoV-2-negative group that received A. satureioides had a faster improvement in the survival analysis of sore throat, earache and loss of appetite. Conclusions: Our findings support the hypothesis that Achyrocline satureioides inflorescence infusions may offer therapeutic benefits in the management of mild viral respiratory infections, as its administration was associated with a significantly accelerated resolution of clinical symptoms. This study was registered in the Brazilian Registry of Clinical Trials (ReBEC; registration number RBR-8g6f2rv) on 27 January 2022.

Open Access PDF

Concepts Keywords
8g6f2rv cold
Argentina coronavirus
Medicine COVID-19
Randomized flu
Viral herbal medicine
macela
medicinal plant

Semantics

Type Source Name
disease MESH Infection
disease MESH COVID-19
disease IDO symptom
disease MESH sore throat
disease MESH respiratory infections
drug DRUGBANK Ribostamycin
drug DRUGBANK Coenzyme M
disease MESH dyspnea
disease MESH Education Level
disease MESH Hypertension
disease MESH Obesity
disease MESH Heart diseases
disease MESH Neoplasias
disease MESH Respiratory diseases
disease MESH viral infection
drug DRUGBANK Mefenamic acid
drug DRUGBANK Acetaminophen
disease IDO pathogen
disease MESH parainfluenza
disease MESH influenza
disease IDO bacteria
disease MESH inflammation
disease MESH edema
drug DRUGBANK Quercetin
disease MESH lung injury
drug DRUGBANK Acetylcholine
disease IDO host
disease IDO protein
pathway KEGG Viral replication
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Water
disease IDO intervention
disease IDO country
disease IDO immune response
disease IDO cell
disease MESH reinfection
drug DRUGBANK beta-Sitosterol
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Aspartame
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Isoxaflutole
disease MESH allergies
disease IDO blood
drug DRUGBANK Etoperidone
drug DRUGBANK Sulfasalazine
disease IDO process
disease MESH COPD
drug DRUGBANK PDE4
disease MESH Coronavirus Infections
drug DRUGBANK Genistein
drug DRUGBANK Carboxyamidotriazole
disease IDO infectivity
drug DRUGBANK Troleandomycin
disease MESH Clinical Significance
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Green tea leaf
drug DRUGBANK Leptin
disease MESH Overweight
disease MESH Dyslipidemia
disease IDO susceptibility
pathway REACTOME Influenza Infection
disease IDO replication
disease MESH Complications

Original Article

(Visited 4 times, 1 visits today)